anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, endocrinology, pharmacy. SUBSTANCE: invention relates to medicinal preparation with an antidiabetic effect. Invention proposes the pharmaceutical composition with an antidiabetic effect containing effective dose of gliclazide and saccharide, microcrystalline cellulose, starch, hydroxypropylmethylcellulose, talc and stearate used as special additions. Pharmaceutical composition is made as tablets. Invention describes method of preparing the pharmaceutical composition including mixing powders of active component with saccharide, microcrystalline cellulose and starch, moistening mixture with 3-% solution of hydroxypropylmethyl-cellulose followed by granulation, drying of moist granulate, dry granulation, powdering mass with a mixture consisting of stearate, talc and starch and tabletting in tablet machine. EFFECT: improved method of preparing, valuable medicinal property. 8 cl, 1 tbl, 3 ex
To ensure full fluorescence and patient comfort, the Ful-Glo impregnated tip should be moistened before application. One or two drops of sterile irrigation solution should be used for this purpose. Touch conjunctiva or fornix as required with moistened tip. It is recommended that the patient blink several times after application. 

NOTE: Contents may not be sterile if individual strip package has been damaged or previously opened. Store below 30°C.
Disclosed are methods and compositions for protecting cells and tissue from damage, particularly damage induced by a cytotoxic agent or a therapeutic treatment. The methods includes contacting a progenitor cell with a member of the FRIL family of progenitor cell preservation factors. Also disclosed are methods for protecting normal cells and tissues in an animal from cytotoxicity induced by a therapeutic treatment, such as chemotherapy or radiotherapy. These methods include administering a FRIL family member molecule to the animal receiving the therapeutic treatment, wherein the normal cells and tissues of the animal administered the FRIL family member are protected from the therapeutic treatment's cytotoxicity. Also disclosed are methods for isolating a cell for repairing a tissue. The methods include contacting a population of cells with a FRIL family member molecule and isolating a cell specifically bound by the FRIL family member molecule, wherein the cell bound to the FRIL family member molecule is useful for repairing a tissue.
FIELD: medicine, oncology. SUBSTANCE: the suggested innovation deals with treating local malignant neoplasms of different localization. It is suggested to carry out local UHF- hyperthermia, moreover, before each seance of local thermochemothermia one should inject not less than 5 U oxytocin into tumor-surrounding tissues. The present method enables to increase tumor respectability and increase life duration in patients. EFFECT: higher efficiency of therapy. 2 ex
This invention demonstrated a new polymer vesicle system structured with an asymmetric membrane which is formed from two amphiphilic di-block (A-B type) copolymers having different hydrophilic blocks or from a tri-block copolymer (A-B-C type) with two different hydrophilic blocks at each end. With this system bio-molecules or macromolecules can be nano- or submicron encapsulated by thermodynamic partition and be stabilized thermodynamically. This system is applicable in particulate and delivery of bio-therapeutics. What equally important in this invention is the method for forming polymer vesicles of asymmetric membrane: phase-guided self-assembly. This method involving hydrophilic two-phase system to guide the block copolymers above to align on the hydrophilic interface in designed orientation. This method will have great application in functionizing or bio-functionizing particulate surfaces.
Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
FIELD: technology of protein purification. SUBSTANCE: method involves the use of column preparative low pressure chromatography including insulin-raw aqueous solution (at pH = 3.0-3.5) passing through ionite - product copolymerization of methacrylic, acrylic acids and ethylene glycol dimethacrylate at swelling degree value K= 4.5-4.8, complete exchange capacity 9.2-9.8 mg x eq./g. Process is carried out by passing insulin-raw through indicated ionite equilibrated with 10-16% aqueous isopropanol solution at pH =3.0-3.5. Then ionite is impregnated with 10-16% aqueous isopropanol solution (pH = 3.0-3.5) and insulin is eluted with 20-25% aqueous isopropanol solution (pH = 3.4-3.9) containing 0.05-0.15 M ammonium acetate. From obtained eluate the end product is isolated by precipitation. Insulin purification degree is increased to 98.7%. EFFECT: increased purification of insulin.
Breathing exercises and calisthenic exercises will be taught to the training group, and they will be followed under the supervision of a physiotherapist for 8 weeks, 3 days a week. Evaluations will be made before and after treatment. Individuals in the calisthenic exercise group will be given exercise training at the level of 65%-80% of the maximal heart rate for 30-40 minutes, 3 days a week for 8 weeks.
Patients receive mFOLFOX6 (leucovorin IV, oxaliplatin IV, and fluorouracil IV), pembrolizumab IV, and propranolol PO on study. Patients also undergo tumor biopsy during screening and CT scans and collection of blood samples during screening and on study.
Participants received single dose of Metformin 1000 milligram (mg) and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 2. Each treatment period was separated by a 14-day wash-out period.
Diabetes is a significant risk factor for chronic kidney disease (CKD) and a primary cause of global morbidity and mortality, resulting in significant costs to healthcare systems. The management of diabetic CKD in the primary care setting remains an ongoing challenge despite the current best practices in the quality of care. This study evaluated family medicine physicians' knowledge and confidence regarding managing CKD in the Eastern Province of Saudi Arabia. A self-administered online questionnaire was distributed to physicians through various social media sites and email lists. The largest number of participants reported a full confidence in knowing kidney disease stages, blood pressure targets and the importance of urine albumin-creatinine ratio testing. Overall, 71.8% of physicians reported a high confidence level, followed by 23.9% reporting average and 4.2% reporting low confidence. Being younger and working at PHC were identified as significant predictors of increased confidence. Although most of the physicians reported a high confidence in managing CKD patients, the need for improvement was evident. Age and workplace institutions were the greater contributors to physicians' confidence. Continuous education among healthcare practitioners is crucial to updating knowledge and providing optimum quality of care among this group of patients.
###  Tardive Dyskinesia

The syndrome is characterized by involuntary choreoathetoid movements which variously involve the tongue, face, mouth, lips, or jaw (e.g., protrusion of the tongue, puffing of cheeks, puckering of the mouth, chewing movements), trunk and extremities. The severity of the syndrome and the degree of impairment produced vary widely.

The syndrome may become clinically recognizable either during treatment, upon dosage reduction, or upon withdrawal of treatment. Movements may decrease in intensity and may disappear altogether if further treatment with neuroleptics is withheld. It is generally believed that reversibility is more likely after short rather than long term neuroleptic exposure. Consequently, early detection of tardive dyskinesia is important. To increase the likelihood of detecting the syndrome at the earliest possible time, the dosage of neuroleptic drug should be reduced periodically (if clinically possible) and the patient observed for signs of the disorder. It has been suggested that fine vermicular movements of the tongue may be an early sign of the syndrome, and that the full blown syndrome may not develop if medication is stopped when lingual vermiculation appears.

1.
     Dystonia: Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups. 
2.
     Akathisia: Akathisia presents as constant motor restlessness. The patient with akathisia often complains, when asked, about his/her inability to stop moving. Akathisia should not be treated with an increased dose of neuroleptic; rather, the dose of antipsychotic may be lowered until the motor restlessness has subsided. The efficacy of anticholinergic treatment of this side effect is unestablished. 
3.
     Pseudoparkinsonism: Pseudoparkinsonism refers to a drug-induced state similar to the classic syndrome. Generally, anticholinergic antiparkinsonian agents (i.e., benztropine, biperiden, procyclidine, or trihexphenidyl) and amantadine are helpful in alleviating symptoms that cannot be managed by neuroleptic dose reduction. The value of prophylactic antiparkinsonian drug therapy has not been established. The need for continued use of antiparkinsonian medication should be reevaluated periodically.
Milrinone infusion at 0.33µg/kg/min. The dose of the study drug will be increased to 0.66 µg/kg/min if oxygenation index (OI) remains ≥ 10 without any evidence of hypotension (as defined by the protocol) two hours after initiation of study drug. Infusion will be continued until the OI decreases to \< 7. The maximum duration of study drug infusion is 72 hours.
There is a composition for maximizing NAD enzyme's health benefits. The composition includes a nucleoside; the nucleoside is adenosine. The nucleoside is a phosphate derivative; wherein the composition includes 1 to 5 percent weight of adenosine. The composition includes a vitamin B3; wherein the vitamin B3 is in the form of niacin, niacinamide, nicotinic acid or nicotinamide. The composition includes 0.1 to 10 percent weight of the Vitamin B3. The composition includes a nicotinamide mononucleotide. The composition includes a stilbene derivative; wherein the composition includes 0.1 to 5 percent weight stilbene derivative.
Subjects will be randomized, with stratification by baseline sodium \<130 or ≥ 130 mEq/L\[mmol/L\] to receive either tolvaptan 15 mg tablet or matching placebo tablet at doses of 15, 30 or 60 mg for 21 days. During this period, fluid restrictions should be loosened or suspended, until the subject's response to therapy can be evaluated, typically over the first few days of therapy. Fluid restriction may be reinstituted at any time in subjects whose sodium fails to improve or worsens with study therapy. A forced-titration up to 60 mg of study drug by day 3 to 7 will be based on the subject's serum sodium Subjects entering the study with a serum sodium concentration less than 130 mEq/L\[mmol/L\] may be fluid restricted if necessary at the discretion of the Investigator. Subjects should be monitored closely during the first 24 hours of treatment for dosing titration. The total dosing duration will be up to 21 days (plus 3 day treatment window). Subjects will return to the clinic on Day 22 (+3 days) for assessments and will complete a follow-up visit on Day 28 (+2 days).
1,211,564. Pharmacologically active substance. FARBWERKE HOECHST A.G. 16 Feb., 1968 [16 Feb., 1967], No. 7712/68. Heading C2C. A novel pharmacologically active substance is isolated from Cabucala madagascariensis by extracting it from the dried material of the plant, suitably by using an alcohol, and if desired converting the active substance isolated from the extract into a physiologically tolerable salt. The novel substance is characterized by the following data: Pharmaceutical compositions comprise the novel compound in conjunction with a suitable carrier or diluent for oral or parenteral administration and possess blood-pressure lowering properties.
Patients with chronic heart failure NYHA \>= 2 based on a reduced left ventricular ejection fraction (LV-EF \<= 45%). All patients receive pulmonary artery catheterization and noninvasive pulse contour Analysis.
Post-stroke depression (PSD) is a prevalent mental health issue, and resveratrol (RES) has been implicated in its management. This study aimed to elucidate the impact of RES on PSD. A PSD rat model was established through middle cerebral artery occlusion and chronic unpredictable mild stress. Rats received RES via gavage, and depressive behaviors were evaluated through various measures. Cerebral infarction areas and brain tissue pathology were assessed using TTC and H&E staining. Levels of inflammatory factors (TNF-α/IL-1β/IL-6/IL-10), neurotransmitters (ACH/DA/5-HT/BDNF), and oxidative stress-related indicators (SOD/GSH-Px/MDA), along with the total Nrf2/C-Nrf2/N-Nrf2/HO-1 proteins, were analyzed. The role of the Nrf2/HO-1 pathway was investigated by co-treating rats with RES and either an Nrf2 pathway specific inhibitor (ML385) or activator (dimethyl fumarate). PSD rats exhibited depressive behaviors, disrupted neurotransmitter levels, and oxidative stress markers. RES treatment effectively alleviated these symptoms and activated the Nrf2/HO-1 pathway in PSD rat brain tissues. Co-administration of ML385 attenuated the beneficial effects of RES in PSD rats. Altogether, RES mitigates depressive behaviors, improves cognitive dysfunction, and reduces oxidative stress and inflammatory response in PSD rats. These effects are mediated through the activation of the Nrf2/HO-1 pathway, suggesting RES as a potential therapeutic agent for PSD-related cognitive impairment.
Depression, like many psychiatric disorders, has a genetic component that makes it more likely that members of the same family will have the disorder. Depression in parents, particularly mothers, may put the children at greater risk for depression. When an adolescent whose parent is depressed develops depression himself or herself, treating both the parent and the adolescent may be more effective than treating only the adolescent. This study will test a depression treatment that targets depressed suicidal adolescents with a parent or primary caretaker who is also depressed and has a history of suicidality.

Participation in this study will last 6 months. Participants will be randomly assigned to receive either concurrent parent and adolescent treatment or adolescent only treatment. For those assigned to concurrent treatment, both the adolescent participants and one of their parents will receive individual cognitive behavioral therapy (CBT) counseling sessions and joint family counseling sessions. In the adolescent only treatment condition, adolescent participants will receive individual CBT sessions, but parents will not, and both will receive joint family sessions. Counseling sessions will last 1 hour and occur weekly for 3 months, and then every other week for 3 months. CBT identifies and attempts to change problematic thought patterns. All participants will receive medication consultation if necessary.

Participants will complete assessments at baseline, post-treatment, and 6 months after completing treatment. These assessments will include questionnaires and interviews about depression, suicidal thoughts, mood regulation, behavioral problems, and family. At post-treatment and the 6-month follow-up, participants will also be asked to give feedback about the counseling, medication consultation, and their satisfaction.
Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
A system for evaluating a patient for mental health issues includes a display device, a user interface, a memory, and a control system. The memory contains machine readable medium. The machine readable medium includes machine executable code storing instructions for performing a method. The control system is coupled to the memory, and includes one or more processors. The control system is configured to execute the machine executable code to cause the control system to display, on the display device, a series of questions from mental health questionnaires. The series of questions includes text and answers for each question. From the user interface, a selection of answers of each of the displayed series of questions is received from a patient. Using a Bayesian Decision List, the received selection of answers is processed to output an indication of mental health of the patient.
This invention discloses a method for preparing high-purity 3, 4, 6-trichloropyridazine. The method comprises reacting maleic anhydride with liquid chlorine, hydrazine hydrate and hydrochloric acid at 60-105 deg.C. The mol ratio of hydrazine hydrate, chlotomaleic anhydride and HCl is 0.687:1:1.5. The molecular formula of 3, 4, 6-trichloropyridazine is C4HCl3N2, the molecular weight is 183.42, and the melting point is 57-59 deg.C. The method can obtain high-purity product, and has such advantages as simple process, high production efficiency and low cost. The product can be used as important intermediate for drug synthesis and important raw material for liquid crystal industry.
The invention discloses a porcine epizootic diarrhea virus S1 protein fusion gene and recombinant bacillus megaterium, and their use. An S1 antigen site of an S glycoprotein of the porcine epizootic diarrhea virus is connected to an anchor sequence of a cell wall so that the porcine epizootic diarrhea virus S1 protein fusion gene shown in the formula of SEQ ID No.1 is obtained. The invention further discloses a secrete expression vector containing the porcine epizootic diarrhea virus S1 protein fusion gene. The secrete expression vector containing the porcine epizootic diarrhea virus S1 protein fusion gene is transferred into the bacillus megaterium and a recombinant protein is expressed on the cell wall or the surface of the bacillus megaterium. A result of a western blot experiment shows that the expressed recombinant protein can react with PEDV immune serum so that it is proved that the expressed recombinant protein has the antigenicity the same as antigenicity of the PEDV natural antigen. A post-inducible expression living bacterium immuno-fluorescence test proves that the expressed recombinant protein is positioned on the surface of the recombinant bacillus megaterium. An experiment result shows that the recombinant protein provided by the invention can be prepared into a safe and effective mucosal immune live bacterium vaccine for preventing and treating porcine epizootic diarrhea.
The present invention provides for liposomes formed with alkylammonium fatty acid salts, and methods for manufacturing same. The liposomes of the invention may deliver entrapped load material or materials at the occurrence of a preset triggering condition. Preferred liposomes of the invention are cationic liposomes. The preferred liposomes of the invention are formed with alkylammonium fatty acid salts, e.g., trialkylammonium fatty acid salts of long chain amides. The liposomes of the invention are used to encapsulate both hydrophobic and hydrophilic load materials. The liposomes formed accordingly are capable of delivering their loads upon the occurrence of a trigger or control condition.
Chronic hepatitis B (CHB) leads to liver inflammation and dysfunction, resulting in liver fibrosis and cancer. Nucleos(t)ide analogues (NAs), inhibitors of hepatitis B virus (HBV), specifically suppress HBV replication. We proposed that immune modulation benefits seroconversion by HBsAg loss. However, activation of T lymphocytes also deteriorates hepatic inflammation. Therefore, we intended to investigate the T cell status and its relationship with hepatic functions in CHB patients treated with NAs. Serum markers, including liver function markers AST, ALT, and HBV-infected markers HBV DNA, HBsAg, HBeAg, and HBsAb were measured in the clinical routine. The T cell levels and markers, including CD69, CD107a, CXCR3, and PD-1 were investigated using flow cytometry. Meanwhile, IFNγ, IL-2, and CXCL10 as immune activation markers in the PBMCs were investigated using qPCR. To validate the effects of NAs on T cell status, qPCR and flow cytometry were used to investigate the gene expression in the HepG2 and PLC5 cells treated with NAs, and in the healthy PBMCs treated with the cell-cultured supernatant. We found that NAs significantly suppressed HBV DNA and reduced AST and ALT levels in the CHB patients. Meanwhile, AST and ALT were both positively correlated with activation marker CD107a in CD8+ T cells. In addition, we found that the CHB patients with seroconversion exhibited a higher CD4/CD8 ratio (p < 0.05) compared to non-seroconversion. We demonstrated that NAs potentially induced IFNs and PD-L1 expression in HepG2 and PLC5 cells. Moreover, the collected supernatant from NAs-treated HepG2 significantly activated PBMCs. This study revealed that the reduction of HBV by NAs may be the reason leading to less AST and ALT levels. We further demonstrated that NAs induced IFN expression in hepatic cells to potentially activate T lymphocytes, which was positively associated with AST and ALT levels in the CHB patients. The results may explain the phenomena in clinical that when the virus is reactivated by aborted use of NAs, it causes consequent T cells-mediated severe acute-on-chronic liver injury.
Patients receive standard of care hepatitis A or B vaccine, tetanus toxoid vaccine, and trivalent influenza vaccine and then undergo standard of care treatment external beam radiation therapy and receive standard of care temozolomide. Patients also undergo collection of blood Samples monthly for the first 8 months and then bimonthly for up to 12 months for analysis via flow cytometry, (CFSE) assay, live cell/dead cell distinction assay, and determination of naïve and memory immune response.